Home・Stock List・Vericel Corp

Vericel Corp

Closed

SectorHealthcare

46.28 1.25

Buy Sell

Overview

Share price change

24h

Current

Min

45.71

Max

47.15

Key metrics
By Trading Economics
Income	-30M -6.3M
Sales	-24M 68M
P/E Sector Avg	105.395 64.641
EPS	-0.12
Profit margin	-9.21
Employees	398
EBITDA	-30M -2.9M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+33.81% upside

Market Stats
By TradingEconomics
Market Cap	456M 2.3B
Previous open	45.03
Previous close	46.28

News Sentiment

By Acuity

100%

320 / 340 Healthcare

Vericel Corp Chart

Past performance is not a reliable indicator of future results.

Related News

3 Aug 2026, 20:03 UTC

Correlated Moves

Vericel Corp shares are advancing, supported by significant gains in the broader market and major tech stocks, contributing to positive investor sentiment.

31 Jul 2026, 20:02 UTC

Correlated Moves

Vericel Corp's price is lower today, influenced by declines in the Biotechnology sub-sector and a falling Russell 2000 Index.

30 Jul 2026, 20:36 UTC

Correlated Moves

Vericel Corp shares gained in after-market trading, aligning with a rising Russell 2000 Index. The stock remains above its 20-day moving average.

29 Jul 2026, 19:27 UTC

Correlated Moves

Vericel Corp shares declined during Wednesday's session, continuing a downward trend since Tuesday's close, amid broader market weakness reflected in the Russell 2000 Index.

28 Jul 2026, 21:02 UTC

Vericel Corp shares are lower in after-market trading, reflecting broader market caution amid declines in the Nikkei 225 Index and technology sector concerns.

27 Jul 2026, 20:31 UTC

Vericel Corp shares declined during after-market hours amid unusual selling pressure. The stock remains below its 20-day moving average with no specific news identified.

24 Jul 2026, 19:46 UTC

Correlated Moves

Vericel Corp reported first-quarter revenue of $39.2 million, missing estimates. Shares are lower amid broader market declines affecting small-cap biotechnology stocks.

22 Jul 2026, 20:13 UTC

Vericel Corp shares are trading higher in after-market hours, influenced by broader market volatility amid rising crude oil prices and geopolitical tensions.

21 Jul 2026, 14:31 UTC

Vericel Corp shares are higher, supported by overall market momentum and a recovery in Asian markets, particularly the Nikkei 225 Index.

20 Jul 2026, 17:46 UTC

Correlated Moves

Vericel Corp shares are lower today, aligning with a decline in the ARK Genomic Revolution ETF and the Russell 2000 Index.

Peer Comparison

Price change

Vericel Corp Forecast

Price Target

By TipRanks

33.81% upside

12 Months Forecast

Average 61.5 USD 33.81%

High 72 USD

Low 58 USD

Based on 4 Wall Street analysts offering 12 month price targets forVericel Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Vericel Corp - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.